About the Metastatic Melanoma Session
Metastatic melanoma is a type of skin cancer that typically originates in the skin and can spread to other organs such as the lymph nodes and lungs. It is estimated that between 2% to 4% of the population is affected by metastatic melanoma. Metastatic melanoma is usually caused by the exposure to ultraviolet radiation from the sun or artificial sources, such as tanning beds. As a result, people who spend a lot of time outdoors or who use tanning beds are at a higher risk of developing this type of cancer. Symptoms of metastatic melanoma vary depending on the stage the cancer is in and the organs it has spread to. Common symptoms include changes in the size, shape or color of the existing melanoma lesions, or the development of new moles. Metastatic melanoma can also cause pain and swelling in areas such as the lymph nodes or other organs. Diagnosis of metastatic melanoma usually involves a physical exam and imaging tests, such as x-rays or computed tomography (CT) scans, to look for evidence of spread. A biopsy can also be used to confirm the presence of melanoma. Treatment for metastatic melanoma typically involves a combination of surgical removal of the primary tumor, chemotherapy, and/or targeted or immunotherapy. The goal of treatment is to prevent the cancer from spreading and to find a way to keep it from recurring. As with other types of cancer, early detection is key in treating metastatic melanoma. If you notice any changes in the appearance of moles or other skin lesions, see a physician right away. Regular skin check-ups and examination by a dermatologist is an important step in the prevention and early detection of melanoma and other types of skin cancer.
Featured Speakers — Metastatic Melanoma 2027
Speaker lineup for this track will be announced soon.
Browse all speakers →Recent Research Presented at Metastatic Melanoma Sessions
Selected abstracts from this track will be published here.
Related Scientific Sessions at IDC 2027
Why Attend the Metastatic Melanoma Conference 2027
Present Your Research
Oral and poster slots for original Metastatic Melanoma work, reviewed by the scientific committee.
Network Globally
Meet researchers, clinicians, and industry leaders from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Metastatic Melanoma research and practice.
Hybrid Flexibility
Attend in person in Rome or join virtually — same program, same certificate.
Join IDC 2027 for the Metastatic Melanoma track
Oral and poster slots for your work — in person in Rome or online. Not presenting? Attend as a delegate to learn from the field.
Metastatic Melanoma Conference 2027 — FAQs
What is the Metastatic Melanoma track at IDC 2027?
The Metastatic Melanoma track is a dedicated stream within IDC 2027 covering the latest research, clinical innovation, and best practice in Metastatic Melanoma. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Metastatic Melanoma sessions?
Researchers, clinicians, educators, doctoral students, and industry leaders with an interest in Metastatic Melanoma are all welcome — whether presenting or attending.
Can I present my research in the Metastatic Melanoma track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Metastatic Melanoma sessions?
Yes. IDC 2027 is a hybrid conference — attend the Metastatic Melanoma track in person in Rome or join live online, with on-demand access afterward.
Join the IDC 2027 delegation
Rome · June 21–23, 2027 · Hybrid · in-person & virtual
Attend without presenting.

